Alphanate
Generic: Antihemophilic Factor [Factor VIII]
Daily Dose:
Course Duration:
Cheaper & Alternative Brands (250 IU/vial)
Same active generic (Antihemophilic Factor [Factor VIII]), same form (Injection), exact same strength (250 IU/vial)No other brands currently registered with this exact active generic and dosage form.
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Treatment and prophylaxis of haemorrhagic episodes in patients with haemophilia A, Prophylaxis in severe haemophilia A
Dosage & Administration
Treatment and prophylaxis of haemorrhagic episodes in patients with haemophilia A
: Dosage is individualised based on coagulation tests performed before treatment and at regular intervals during treatment. Generally, 1 IU/kg will increase circulating factor VIII levels by about 2 IU/dL. Recommended doses vary according to the preparation used
Suggested doses
: Mild-moderate haemorrhage (increase to 20-30% of normal): Usually with a single dose of 10-15 IU/kg
More serious haemorrhage or minor surgery (increase to 30-50% of normal)
: Usual initial dose of 15-25 units/kg followed by 10-15 IU/kg every 8-12 hr if required
Severe haemorrhage or major surgery (increase to 80-100% of normal)
: Usual initial dose of 40-50 IU/kg followed by 20-25 IU/kg every 8-12 hr. Refer to individual product information for further dosing details
Prophylaxis in severe haemophilia A
: 10-50 IU/kg every 2-3 days, as needed
Contraindications
In individuals who have had an anaphylactic or severe systemic reaction to antihemophilic factor or von Willebrand factor preparations.
Side Effects & Adverse Reactions
Allergic reactions e.g. chills, chest tightness, fever, headache, hyperfibrinogenaemia, jittery feeling, lethargy, nausea, vomiting, somnolence, stinging at infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion.
Warnings & Precautions
Risk of intravascular haemolysis in patients with blood groups A, B, or AB receiving high doses or repeated doses of factor VIII preparations. Risk of transmission of some viral infections especially hepatitis B and C. Dose requirement may vary in patients with factor VIII inhibitors; thus optimal treatment should be based on clinical response. Monitor platelet counts regularly during treatment.
Pharmacology & Mechanism of Action
Factor VIII is required for clot formation and maintenance of haemostasis. It activates factor X in conjunction with activated factor IX. Activated factor X then converts prothrombin to thrombin, which converts fibrinogen to fibrin, and forms a stable clot with factor XIII. Factor VIII is used for replacement therapy in patients with haemophilia A.